Drugs / Casdozokitug
Casdozokitug
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04374877 | Apr 2020 → May 2025 | clear cell renal carcinoma, hepatocellular carcinoma, non-small cell lung carcinoma | Coherus Oncology, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06679985 | Dec 2024 → Sep 2027 expected | hepatocellular carcinoma | Coherus Oncology, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05359861 | Apr 2022 → Jun 2025 | hepatocellular carcinoma | Coherus Oncology, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Casdozokitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06679985 ↗ |
| Known as | CHS-388 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04374877 ↗ |
| Known as | SRF388 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05359861 ↗ |
| Action | Inhibit | “Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation” NCT04374877 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314661 ↗ |
| Route | Intravenous | “SRF388 will be administered by intravenous injection (IV)” NCT05359861 ↗ |